Citron
All posts
·1 min

Corvention Clears FDA for UHP Balloon

Alan Zajarias used Corvention's KardiaPSI balloon catheter in St. Louis on June 24, 2026. Corvention called that the first U.S. case, and the start of a limited commercial launch. The company is in Flagstaff, Arizona.

On May 11, 2026, Corvention said the FDA had cleared KardiaPSI for balloon aortic valvuloplasty. The company said the balloon delivers 24 atmospheres over a working length of 2.5 centimeters, for dilating a calcified, stenotic aortic valve.

"The device performed exactly as anticipated, remaining very stable in place, with fast inflation/deflation times, that are critical in these complex anatomical environments," said Alan Zajarias.

"This first case lays the foundation for our controlled rollout across elite cardiovascular centers nationwide," said Michael Franklin, chief executive.

Back to all posts